Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5715911 | Annals of Diagnostic Pathology | 2017 | 15 Pages |
Abstract
The μ-bcr breakpoint connects exon 19 of BCR with ABL giving rise to the e19a2 transcript corresponding to the p230 fusion protein (micro-BCR breakpoint) which is rarely seen in chronic myeloid leukemia (CML) patients. Here we report three patients with p230 fusion protein presenting with different clinical presentations and diagnosed as CML-CP. These patients received Imatinib (tyrosine kinase inhibitor-TKI) and are still in remission.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Pathology and Medical Technology
Authors
Sudha Sazawal, Sunita Chikkara, Kanwaljeet Singh, Rekha Chaubey, Dinesh Chandra, Pravas Mishra, Manoranjan Mahapatra, Tulika Seth, Renu Saxena,